PT3300742T - Transferrina para usar no tratamento de condições do tipo isquemia relacionadas com o factor induzido por hipoxia (fih) - Google Patents

Transferrina para usar no tratamento de condições do tipo isquemia relacionadas com o factor induzido por hipoxia (fih)

Info

Publication number
PT3300742T
PT3300742T PT172000655T PT17200065T PT3300742T PT 3300742 T PT3300742 T PT 3300742T PT 172000655 T PT172000655 T PT 172000655T PT 17200065 T PT17200065 T PT 17200065T PT 3300742 T PT3300742 T PT 3300742T
Authority
PT
Portugal
Prior art keywords
hif
transferrin
ischemia
treatment
related conditions
Prior art date
Application number
PT172000655T
Other languages
English (en)
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of PT3300742T publication Critical patent/PT3300742T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PT172000655T 2014-07-11 2015-06-08 Transferrina para usar no tratamento de condições do tipo isquemia relacionadas com o factor induzido por hipoxia (fih) PT3300742T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462023446P 2014-07-11 2014-07-11

Publications (1)

Publication Number Publication Date
PT3300742T true PT3300742T (pt) 2021-01-25

Family

ID=53385523

Family Applications (2)

Application Number Title Priority Date Filing Date
PT15171056T PT2977056T (pt) 2014-07-11 2015-06-08 Transferrina para usar no tratamento de distúrbios neurodegenerativos relacionados com o factor induzido por hipoxia (fih)
PT172000655T PT3300742T (pt) 2014-07-11 2015-06-08 Transferrina para usar no tratamento de condições do tipo isquemia relacionadas com o factor induzido por hipoxia (fih)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT15171056T PT2977056T (pt) 2014-07-11 2015-06-08 Transferrina para usar no tratamento de distúrbios neurodegenerativos relacionados com o factor induzido por hipoxia (fih)

Country Status (26)

Country Link
US (2) US9687530B2 (pt)
EP (3) EP3795171B1 (pt)
JP (1) JP6517100B2 (pt)
KR (3) KR102219557B1 (pt)
CN (1) CN105288598A (pt)
AR (1) AR101133A1 (pt)
AU (3) AU2015203264B2 (pt)
BR (1) BR102015015916A2 (pt)
CA (3) CA3191469A1 (pt)
CL (1) CL2015001936A1 (pt)
ES (2) ES2843783T3 (pt)
FI (1) FI3795171T3 (pt)
HK (1) HK1220895A1 (pt)
HU (1) HUE053104T2 (pt)
IL (1) IL239655B (pt)
MX (1) MX359029B (pt)
MY (1) MY184341A (pt)
NZ (2) NZ757595A (pt)
PL (2) PL3300742T3 (pt)
PT (2) PT2977056T (pt)
RU (1) RU2686308C2 (pt)
SG (2) SG10201811078XA (pt)
TR (1) TR201815058T4 (pt)
TW (1) TWI704926B (pt)
UY (1) UY36173A (pt)
ZA (2) ZA201504705B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107831315B (zh) * 2017-10-31 2019-11-05 中国科学院昆明动物研究所 转铁蛋白标志物及其应用
MX2022016226A (es) * 2020-07-08 2023-02-01 Grifols Worldwide Operations Ltd Composiciones que tienen aplicaciones neuroregenerativas.
AU2021306631A1 (en) * 2020-07-08 2023-02-02 Grifols Worldwide Operations Limited Compositions having neuroregenerative applications
RU2747653C1 (ru) * 2021-01-11 2021-05-11 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ диагностики нарушения обмена железа при тяжелых формах covid-19
EP4052723A1 (en) 2021-03-02 2022-09-07 Grifols Worldwide Operations Limited Alpha-1 antitrypsin dosing regimen
EP4311556A1 (en) 2022-07-28 2024-01-31 Grifols Worldwide Operations Limited Antithrombin in stroke

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419365A (en) * 1981-12-21 1983-12-06 Ciba-Geigy Corporation Method of treating Alzheimer's disease
US5110722A (en) * 1989-11-09 1992-05-05 Cryolife, Inc. Cell, tissue or organ storage solution
US5986067A (en) * 1991-02-08 1999-11-16 The University Of Vermont And State Agricultural College Recombinant transferrins, transferrin half-molecules and mutants thereof
EP1143253A1 (en) * 1992-07-10 2001-10-10 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
IT1278136B1 (it) * 1995-07-12 1997-11-17 Piera Valenti Associazione costituita dsa lattoferrina (o suoi analoghi) e deferossamina metalsulfonato (o altri chelanti ioni metallici) per
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US6004986A (en) * 1997-05-08 1999-12-21 The University Of Virginia Patent Foundation Method for treating cerebral vasospasm and cerebral ischemia using iron chelators and pharmaceutical compositions therefor
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US20020164571A1 (en) 2001-03-02 2002-11-07 Hammerman Marc R. Method of preserving metanephroi in vitro prior to transplantation
CA3094774A1 (en) 2001-12-06 2003-07-03 Fibrogen, Inc. Use of hif prolyl hydroxylase inhibitors for treating neurological disorders
WO2005018701A1 (en) 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
WO2007048004A2 (en) * 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Compounds for enhancing hypoxia inducible factor activity and methods of use
WO2007076505A2 (en) * 2005-12-28 2007-07-05 Essential Skincare, Llc Transferrin and transferrin-based compositions for diabetes treatment
WO2007081654A2 (en) * 2005-12-28 2007-07-19 Zoltan Laboratories Llc Compositions and methods to enhance viability and function of islet cells
EP2327696A1 (en) 2006-06-26 2011-06-01 Warner Chilcott Company, LLC Prolyl hydroxylase inhibitors and methods of use
WO2008113134A1 (en) * 2007-03-20 2008-09-25 Garvan Institute Of Medical Research Method of transplantation of a kidney
ITLU20070009A1 (it) * 2007-05-21 2008-11-22 Kedrion Spa Uso di transferrina per la preparazione di composizioni farmaceutiche utili per il trattamento di infezioni batteriche come coadiuvanti nella terapia antibiotica.
WO2009055863A1 (en) * 2007-11-01 2009-05-07 The University Of Sydney Desferrioxamine conjugates, derivatives and analogues
MX2013014310A (es) 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
CN103930103B (zh) 2011-10-12 2016-08-24 思佰益药业股份有限公司 移植器官的成活促进剂
US9492509B2 (en) * 2011-11-11 2016-11-15 Fundaciö Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Apotransferrin for the treatment of brain stroke
WO2014100233A1 (en) * 2012-12-19 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Iron chelators and use thereof for reducing transplant failure during rejection episodes

Also Published As

Publication number Publication date
RU2686308C2 (ru) 2019-04-25
SG10201505207RA (en) 2016-02-26
US9687530B2 (en) 2017-06-27
AU2021201445A1 (en) 2021-03-25
ES2843783T3 (es) 2021-07-20
MX2015008310A (es) 2016-01-11
AU2019264588B2 (en) 2021-03-25
AU2015203264B2 (en) 2019-08-22
CA2894239A1 (en) 2016-01-11
CA3191475A1 (en) 2016-01-11
EP2977056B1 (en) 2018-09-12
USRE49129E1 (en) 2022-07-12
JP2016020342A (ja) 2016-02-04
ZA201504705B (en) 2022-09-28
EP3795171B1 (en) 2024-04-10
AR101133A1 (es) 2016-11-23
CA2894239C (en) 2023-05-09
EP2977056A3 (en) 2016-04-27
KR20210021339A (ko) 2021-02-25
KR20160007367A (ko) 2016-01-20
SG10201811078XA (en) 2019-01-30
ES2693602T3 (es) 2018-12-12
EP3300742B1 (en) 2020-11-04
PL3300742T3 (pl) 2021-05-04
ZA202203445B (en) 2022-09-28
EP2977056A2 (en) 2016-01-27
FI3795171T3 (fi) 2024-05-10
AU2021201445B2 (en) 2024-02-29
KR102219557B1 (ko) 2021-02-24
HK1220895A1 (zh) 2017-05-19
CL2015001936A1 (es) 2015-12-28
TWI704926B (zh) 2020-09-21
CN105288598A (zh) 2016-02-03
AU2019264588A1 (en) 2019-12-05
TW201622742A (zh) 2016-07-01
KR102310000B1 (ko) 2021-10-07
US20160008437A1 (en) 2016-01-14
EP3300742A1 (en) 2018-04-04
MY184341A (en) 2021-04-01
JP6517100B2 (ja) 2019-05-22
BR102015015916A2 (pt) 2016-01-12
CA3191469A1 (en) 2016-01-11
IL239655B (en) 2019-07-31
RU2015126920A (ru) 2017-01-10
NZ757595A (en) 2024-01-26
AU2015203264A1 (en) 2016-01-28
PL2977056T3 (pl) 2019-03-29
TR201815058T4 (tr) 2018-11-21
RU2015126920A3 (pt) 2019-01-15
KR20190132966A (ko) 2019-11-29
PT2977056T (pt) 2018-11-07
NZ709399A (en) 2019-10-25
MX359029B (es) 2018-09-12
HUE053104T2 (hu) 2021-06-28
EP3795171A1 (en) 2021-03-24
UY36173A (es) 2016-02-29

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
HK1220895A1 (zh) 用於治療缺氧誘導因子 相關的狀況如局部缺血的轉鐵蛋白
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
IL251905A0 (en) Epilimod for use in the treatment of kidney cancer
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL250507B (en) Anti-ck8 antibodies for use in cancer treatment
IL251904A0 (en) Epilimod for use in the treatment of melanoma
PL2952406T3 (pl) Wózek i przyczepa
PL3279327T3 (pl) Nowy promotor i jego zastosowanie
GB201400311D0 (en) Treating Susceptibility
GB201513233D0 (en) Sling with steering strips
GB201409400D0 (en) Trophy with removable band
EP3713604C0 (de) Verbindung zur anwendung bei der steigerung von mentaler leistungsfähigkeit
GB201421889D0 (en) Improvements in or relating to effluent treatment